![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » Pharma Blog Watch
Pharma Blog Watch
Torcetrapib
Troubles (Pharma's Cutting Edge)
In his blog, Fred Cohen discusses data recently released by Pfizer on its investigational
cholesterol drug torcetrapib "Pfizer's best hope for replacing Lipitor
sales when Lipitor goes off patent" showing the drug caused a rise
in systolic blood pressure. "Does this blood pressure finding, 1-2 mm higher
than what was seen in Phase II, really change the outlook for approval? Yes
and no," he writes. "I think what it does is cement the need for an
outcomes study preapproval, but I also think this was likely to be required
anyway, and Pfizer was simply being overly optimistic to the public after Phase
II."
"Finally, I wouldn't try to transfer the experience of torcetrapib to therapies aimed at increasing HDL-C through mechanisms other than CETP inhibition. The only relevant lesson is that sponsors must expect and plan for an outcomes study preapproval for virtually any chronic-use cardiovascular drug with a new mechanism of action. Plaque reduction studies are nice but aren't going to cut it for most new drugs."
Reevaluating
Risk (Health Business Blog)
In his entry, blogger David Williams writes about a talk Biogen Idec's CEO Jim
Mullen gave at a conference last week. Mullen spoke about drug risk. "He
wants us to regain perspective on risk," Williams writes. "The 'safe
and effective' mantra doesn't make sense. Actually drugs are inherently unsafe,
even OTC products. Instead we should look at the risk of unforeseen outcomes
(i.e., adverse events) versus the risk of forgoing therapy."
"Naturally he offered the example of Biogen's Tysabri, an effective drug against [multiple sclerosis] that can cause a deadly brain infection. From the FDA's perspective, keeping the drug off the market was good because it meant avoiding harm, but patients looked at it differently: many wanted Tysabri back because they were willing to take the risk," he writes.
KEYWORDS Drug Pipeline Alert
Upcoming Events
-
21Oct